Genetic alterations in systemic nodal and extranodal non-cutaneous lymphomas derived from mature T cells and natural killer cells

Cancer Science

Volumn 103, Issue 8, 2012, Pages 1397-1404

  Boi, Michela ^a   Stathis, Anastasios ^b   Zucca, Emanuele ^b   Inghirami, Giorgio ^c,d   Bertoni, Francesco ^a,b  

^a INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^c UNIVERSITY OF TURIN   (Italy)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BELINOSTAT; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CARFILZOMIB; CYCLOPHOSPHAMIDE; DARINAPARSIN; DENILEUKIN DIFTITOX; DEXAMETHASONE; DOXORUBICIN; ENDOSTATIN; ETOPOSIDE; EVEROLIMUS; LENALIDOMIDE; MOGAMULIZUMAB; PANOBINOSTAT; PREDNISOLONE; RITUXIMAB; ROMIDEPSIN; SIPLIZUMAB; VINCRISTINE; VORINOSTAT;

ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; B CELL LYMPHOMA; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; ENTEROPATHY ASSOCIATED T CELL LYMPHOMA; GENE EXPRESSION PROFILING; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMATOID PAPULOSIS; LYMPHOPROLIFERATIVE DISEASE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MYCOSIS FUNGOIDES; NATURAL KILLER CELL; NK T CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; REVIEW; SEZARY SYNDROME; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE; WORLD HEALTH ORGANIZATION;

HUMANS; KILLER CELLS, NATURAL; LYMPH NODES; LYMPHOMA; LYMPHOMA, T-CELL; T-LYMPHOCYTES;

EID: 84864300457     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02321.x     Document Type: Review

References (87)

1. Swerdlow SH, Campo E, Harris NL et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2008; 439.
2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124-30.
3. Weisenburger DD, Savage KJ, Harris NL et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011; 117: 3402-8.
4. Armitage JO. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87: 511-9.
5. Martinez-Delgado B. Peripheral T-cell lymphoma gene expression profiles. Hematol Oncol 2006; 24: 113-9.
6. Rudiger T, Geissinger E, Muller-Hermelink HK. 'Normal counterparts' of nodal peripheral T-cell lymphoma. Hematol Oncol 2006; 24: 175-80.
7. Costello R, Sanchez C, Le Treut T, Rihet P, Imbert J, Sebahoun G. Peripheral T-cell lymphoma gene expression profiling and potential therapeutic exploitations. Br J Haematol 2010; 150: 21-7.
8. Lepretre S, Buchonnet G, Stamatoullas A et al. Chromosome abnormalities in peripheral T-cell lymphoma. Cancer Genet Cytogenet 2000; 117: 71-9.
9. Renedo M, Martinez-Delgado B, Arranz E et al. Chromosomal changes pattern and gene amplification in T cell non-Hodgkin's lymphomas. Leukemia 2001; 15: 1627-32.
10. Melendez B, Diaz-Uriarte R, Cuadros M et al. Gene expression analysis of chromosomal regions with gain or loss of genetic material detected by comparative genomic hybridization. Genes Chromosom Cancer 2004; 41: 353-65.
11. Zettl A, Rudiger T, Konrad MA et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol 2004; 164: 1837-48.
12. Nelson M, Horsman DE, Weisenburger DD et al. Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. Br J Haematol 2008; 141: 461-9.
13. Fujiwara SI, Yamashita Y, Nakamura N et al. High-resolution analysis of chromosome copy number alterations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified, with single nucleotide polymorphism-typing microarrays. Leukemia 2008; 22: 1891-8.
14. Thorns C, Bastian B, Pinkel D et al. Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: a matrix-based CGH approach. Genes Chromosom Cancer 2007; 46: 37-44.
15. Nakagawa M, Nakagawa-Oshiro A, Karnan S et al. Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult T-cell leukemia/lymphoma. Clin Cancer Res 2009; 15: 30-8.
16. Hartmann S, Gesk S, Scholtysik R et al. High resolution SNP array genomic profiling of peripheral T cell lymphomas, not otherwise specified, identifies a subgroup with chromosomal aberrations affecting the REL locus. Br J Haematol 2010; 148: 402-12.
17. Nagel S, Leich E, Quentmeier H et al. Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma. Leukemia 2008; 22: 387-92.
18. Gesk S, Martin-Subero JI, Harder L et al. Molecular cytogenetic detection of chromosomal breakpoints in T-cell receptor gene loci. Leukemia 2003; 17: 738-45.
19. Feldman AL, Law M, Grogg KL et al. Incidence of TCR and TCL1 gene translocations and isochromosome 7q in peripheral T-cell lymphomas using fluorescence in situ hybridization. Am J Clin Pathol 2008; 130: 178-85.
20. Leich E, Haralambieva E, Zettl A et al. Tissue microarray-based screening for chromosomal breakpoints affecting the T-cell receptor gene loci in mature T-cell lymphomas. J Pathol 2007; 213: 99-105.
21. Streubel B, Vinatzer U, Willheim M, Raderer M, Chott A. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia 2006; 20: 313-8.
22. Pechloff K, Holch J, Ferch U et al. The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma. J Exp Med 2010; 207: 1031-44.
23. Dierks C, Adrian F, Fisch P et al. The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease. Cancer Res 2010; 70: 6193-204.
24. Feldman AL, Sun DX, Law ME et al. Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas. Leukemia 2008; 22: 1139-43.
25. Martinez-Delgado B, Cuadros M, Honrado E et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia 2005; 19: 2254-63.
26. Piccaluga PP, Agostinelli C, Zinzani PL, Baccarani M, Dalla Favera R, Pileri SA. Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified. Lancet Oncol 2005; 6: 440.
27. de Leval L, Rickman DS, Thielen C et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007; 109: 4952-63.
28. Piccaluga PP, Agostinelli C, Califano A et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 2007; 117: 823-34.
29. de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol 2010; 148: 673-89.
30. Magrath IT, ed. The Lymphoid Neoplasms, 3rd edn. London: Hodder Arnold, 2010; 1657.
31. Armitage JO, Coiffier B, Dalla FaveraR, Harris NL, Mauch PM, eds. Non-Hodgkin Lymphomas, 2nd edn. Philadelphia, PA, USA: Lippincott Williams & Wilkins, 2010; 597.
32. Attygalle AD, Chuang SS, Diss TC, Du MQ, Isaacson PG, Dogan A. Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Histopathology 2007; 50: 498-508.
33. Schlegelberger B, Zhang Y, Weber-Matthiesen K, Grote W. Detection of aberrant clones in nearly all cases of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma by combined interphase and metaphase cytogenetics. Blood 1994; 84: 2640-8.
34. Piccaluga PP, Agostinelli C, Califano A et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res 2007; 67: 10703-10.
35. Iqbal J, Weisenburger DD, Greiner TC et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 2010; 115: 1026-36.
36. Zhao WL, Mourah S, Mounier N et al. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest 2004; 84: 1512-9.
37. Aguiar Bujanda D. Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab. Ann Oncol 2008; 19: 396-7.
38. Ruan J, Hajjar K, Rafii S, Leonard JP. Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol 2009; 20: 413-24.
39. Fornari A, Piva R, Chiarle R, Novero D, Inghirami G. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? Hematol Oncol 2009; 27: 161-70.
40. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008; 8: 11-23.
41. Morris SW, Kirstein MN, Valentine MB et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-4.
42. Zamo A, Chiarle R, Piva R et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002; 21: 1038-47.
43. Falini B, Pulford K, Pucciarini A et al. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood 1999; 94: 3509-15.
44. Ott G, Katzenberger T, Siebert R et al. Chromosomal abnormalities in nodal and extranodal CD30+ anaplastic large cell lymphomas: infrequent detection of the t(2;5) in extranodal lymphomas. Genes Chromosom Cancer 1998; 22: 114-21.
45. Salaverria I, Bea S, Lopez-Guillermo A et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol 2008; 140: 516-26.
46. Youssif C, Goldenbogen J, Hamoudi R et al. Genomic profiling of pediatric ALK-positive anaplastic large cell lymphoma: a Children's Cancer and Leukaemia Group Study. Genes Chromosom Cancer 2009; 48: 1018-26.
47. Tsukasaki K, Krebs J, Nagai K et al. Comparative genomic hybridization analysis in adult T-cell leukemia/lymphoma: correlation with clinical course. Blood 2001; 97: 3875-81.
48. Piva R, Agnelli L, Pellegrino E et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J Clin Oncol 2010; 28: 1583-90.
49. Thompson MA, Stumph J, Henrickson SE et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum Pathol 2005; 36: 494-504.
50. Lamant L, de Reynies A, Duplantier MM et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 2007; 109: 2156-64.
51. Merkel O, Hamacher F, Sifft E, Kenner L, Greil R. Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools. Mol Cancer Ther 2011; 10: 1127-36.
52. Chiarle R, Martinengo C, Mastini C et al. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med 2008; 14: 676-80.
53. Falini B, Pileri S, Zinzani PL et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999; 93: 2697-706.
54. Boi M, Rinaldi A, Piva R et al. BLIMP1 Is Commonly Inactivated In Anaplastic Large T-Cell Lymphomas (ALCL). ASH Annual Meeting Abstracts 2011; 118: 2634.
55. Karube K, Nakagawa M, Tsuzuki S et al. Identification of FOXO3 and PRDM1 as tumor suppressor gene candidates in NK cell neoplasms by genomic and functional analyses. Blood 2011; 118: 3195-204.
56. Kucuk C, Iqbal J, Hu X et al. PRDM1 is a tumor suppressor gene in natural killer cell malignancies. Proc Natl Acad Sci U S A 2011; 108: 20119-24.
57. Fischer TC, Gellrich S, Muche JM et al. Genomic aberrations and survival in cutaneous T cell lymphomas. J Invest Dermatol 2004; 122: 579-86.
58. van Kester MS, Tensen CP, Vermeer MH et al. Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators. J Invest Dermatol 2010; 130: 563-75.
59. Bekkenk MW, Geelen FA, van Voorst Vader PC et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95: 3653-61.
60. Feldman AL, Dogan A, Smith DI et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood 2011; 117: 915-9.
61. Desjobert C, Renalier MH, Bergalet J et al. MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression. Blood 2011; 117: 6627-37.
62. Feldman AL, Law M, Remstein ED et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia 2009; 23: 574-80.
63. Pham-Ledard A, Prochazkova-Carlotti M, Laharanne E et al. IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases. J Invest Dermatol 2010; 130: 816-25.
64. Suzuki R, Takeuchi K, Ohshima K, Nakamura S. Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol 2008; 26: 66-72.
65. Siu LL, Chan V, Chan JK, Wong KF, Liang R, Kwong YL. Consistent patterns of allelic loss in natural killer cell lymphoma. Am J Pathol 2000; 157: 1803-9.
66. Siu LL, Wong KF, Chan JK, Kwong YL. Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. Am J Pathol 1999; 155: 1419-25.
67. Nakashima Y, Tagawa H, Suzuki R et al. Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/T-cell lymphoma, nasal type. Genes Chromosom Cancer 2005; 44: 247-55.
68. Iqbal J, Kucuk C, Deleeuw RJ et al. Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia 2009; 23: 1139-51.
69. Ko YH, Choi KE, Han JH, Kim JM, Ree HJ. Comparative genomic hybridization study of nasal-type NK/T-cell lymphoma. Cytometry 2001; 46: 85-91.
70. Berti E, Recalcati S, Girgenti V, Fanoni D, Venegoni L, Vezzoli P. Cutaneous extranodal NK/T-cell lymphoma: a clinicopathologic study of 5 patients with array-based comparative genomic hybridization. Blood 2010; 116: 165-70.
71. Hongyo T, Hoshida Y, Nakatsuka S et al. p53, K-ras, c-kit and beta-catenin gene mutations in sinonasal NK/T-cell lymphoma in Korea and Japan. Oncol Rep 2005; 13: 265-71.
72. Huang Y, de Reynies A, de Leval L et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood 2010; 115: 1226-37.
73. Ng S-B, Yan J, Huang G et al. Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood 2011; 118: 4919-29.
74. Ng SB, Selvarajan V, Huang G et al. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J Pathol 2011; 223: 496-510.
75. Deleeuw RJ, Zettl A, Klinker E et al. Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology 2007; 132: 1902-11.
76. Delabie J, Holte H, Vose JM et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood 2011; 118: 148-55.
77. Zettl A, Ott G, Makulik A et al. Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. Am J Pathol 2002; 161: 1635-45.
78. Ko YH, Karnan S, Kim KM et al. Enteropathy-associated T-cell lymphoma-a clinicopathologic and array comparative genomic hybridization study. Hum Pathol 2010; 41: 1231-7.
79. Takeshita M, Nakamura S, Kikuma K et al. Pathological and immunohistological findings and genetic aberrations of intestinal enteropathy-associated T cell lymphoma in Japan. Histopathology 2011; 58: 395-407.
80. Cejkova P, Zettl A, Baumgartner AK et al. Amplification of NOTCH1 and ABL1 gene loci is a frequent aberration in enteropathy-type T-cell lymphoma. Virchows Arch 2005; 446: 416-20.
81. Belhadj K, Reyes F, Farcet JP et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003; 102: 4261-9.
82. Cooke CB, Krenacs L, Stetler-Stevenson M et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 1996; 88: 4265-74.
83. Miyazaki K, Yamaguchi M, Imai H et al. Gene expression profiling of peripheral T-cell lymphoma including gammadelta T-cell lymphoma. Blood 2009; 113: 1071-4.
84. Alonsozana EL, Stamberg J, Kumar D et al. Isochromosome 7q: the primary cytogenetic abnormality in hepatosplenic gammadelta T cell lymphoma. Leukemia 1997; 11: 1367-72.
85. Travert M, Huang Y, de Leval L et al. Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets. Blood 2012 (in press).
86. Willemze R, Jansen PM, Cerroni L et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 2008; 111: 838-45.
87. Hahtola S, Burghart E, Jeskanen L et al. Clinicopathological characterization and genomic aberrations in subcutaneous panniculitis-like T-cell lymphoma. J Invest Dermatol 2008; 128: 2304-9.